Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

real-time data

- PMLiVE

Paul Blake joins Oxford BioMedica

He will lead the development of pipeline of gene and cell therapies

Roche - Basel

Roche boosts respiratory presence with InterMune purchase

Deal is fourth takeover in three months for Swiss pharma company

- PMLiVE

Merck and Advaxis to study anti-PD1 combo

Collaboration to investigate pembrolizumab and ADXS-PSA in prostate cancer

- PMLiVE

ViiV bags US approval for HIV blockbuster-in-waiting

Drug combines antiretrovirals with Tivicay

- PMLiVE

AZ launches DoctorsNotes online medical literature tool

New browser extension aims to make HCP's reading 'shareable and social'

- PMLiVE

Novo launches diabetes campaign in Copenhagen

Follows introduction of ‘Cities Changing Diabetes’ programme in Mexico

Elliott Levy joins Amgen from BMS

He is appointed senior VP, global development

- PMLiVE

Alternative medicine studies criticised by researchers

Academics call to end clinical trials involving "highly implausible treatments" such as homeopathy

Easier access to medicines in the UK?

Cutting through the NICE value-based assessment consultation to find out what’s at stake

- PMLiVE

Easier access to medicines in the UK?

Cutting through the NICE value-based assessment consultation to find out what’s at stake

Exploring MINT: Part 3 – Nigeria

In the third of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Nigeria.

Inizio

- PMLiVE

Lilly’s psoriasis candidate tops Enbrel in phase III trials

Ixekizumab on course for regulatory filing in first half of 2015

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links